title: DermAll nanomedicine for allergen-specific immunotherapy.
abstract: Allergen-specific immunotherapy (ASIT) the only disease-modifying treatment for IgE-mediated allergies is characterized with long treatment duration and high risk of side effects. We investigated the safety, immunogenicity and efficacy of a novel ASIT, called DermAll, in an experimental allergic rhinitis model. We designed and characterized DermAll-OVA, a synthetic plasmid pDNA/PEIm nanomedicine expressing ovalbumin (OVA) as model allergen. DermAll-OVA was administered topically with DermaPrep device to target Langerhans cells. To detect the clinical efficacy of DermAll ASIT we quantified the nasal symptoms and characterized the immunomodulatory activity of DermAll ASIT by measuring cytokine secretion after OVA-stimulation of splenocytes and antibodies from the sera. In allergic mice DermAll ASIT was as safe as Placebo, balanced the allergen-induced pathogenic TH2-polarized immune responses, and decreased the clinical symptoms by 52% [32%, 70%] compared to Placebo. These studies suggest that DermAll ASIT is safe and should significantly improve the immunopathology and symptoms of allergic diseases.
  
  
  BACKGROUND
  A novel allergen-specific immunotherapy for IgE-mediated allergies is presented in this paper, using an experimental allergic rhinitis model and a synthetic plasmid pDNA/PEIm nanomedicine expressing ovalbumin as model allergen. Over 50% reduction of symptoms was found as the immune system's balance was favorably altered toward more TH2-polarized immune responses.
authors.affiliation: Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary; Genetic Immunity, Budapest, Hungary; McLean, VA, USA.
authors.forename: Edina
authors.initials: E
authors.lastname: Garaczi
authors.forename: Kornélia
authors.initials: K
authors.lastname: Szabó
authors.forename: László
authors.initials: L
authors.lastname: Francziszti
authors.forename: Zsolt
authors.initials: Z
authors.lastname: Csiszovszki
authors.forename: Orsolya
authors.initials: O
authors.lastname: Lőrincz
authors.forename: Enikő R
authors.initials: ER
authors.lastname: Tőke
authors.forename: Levente
authors.initials: L
authors.lastname: Molnár
authors.forename: Tamás
authors.initials: T
authors.lastname: Bitai
authors.forename: Tamás
authors.initials: T
authors.lastname: Jánossy
authors.forename: Zsuzsanna
authors.initials: Z
authors.lastname: Bata-Csörgő
authors.forename: Lajos
authors.initials: L
authors.lastname: Kemény
authors.forename: Julianna
authors.initials: J
authors.lastname: Lisziewicz
mesh_terms: D000287:Administration, Topical; D000485:Allergens / Q000235:genetics / Q000276:immunology*; D000818:Animals; D016207:Cytokines / Q000276:immunology; D005260:Female; D007114:Immunization; D007073:Immunoglobulin E / Q000097:blood / Q000276:immunology; D007801:Langerhans Cells / Q000276:immunology / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D050997:Nanomedicine; D010047:Ovalbumin / Q000235:genetics / Q000276:immunology*; D010957:Plasmids / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D065631:Rhinitis, Allergic; D012221:Rhinitis, Allergic, Perennial / Q000097:blood / Q000276:immunology* / Q000517:prevention & control*; D018418:Th2 Cells / Q000276:immunology; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology* / Q000627:therapeutic use*
chemical_list: D000485:Allergens; D016207:Cytokines; D019444:Vaccines, DNA; D007073:Immunoglobulin E; D010047:Ovalbumin
keywords: AR; ASIT; DermaVir; EPIT; Epicutaneous Immunotherapy; LCs; Langerhans cells; Nanomedicine; OVA; PEIm; allergen-specific immunotherapy; allergic rhinitis; epicutaneous immunotherapy; ovalbumin; pDNA; plasmid DNA; polyethylenimine-mannobiose